Big Pharma’s China deal spree grows with latest tie-up worth up to $7.8 billion

Fecha de publicación: 2 de octubre de 2026, 12:31

Western biopharma companies are increasingly turning to China to source innovation, as pharma's dreaded "patent cliff" draws closer.